title: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
authors.affiliation: European Institute of Oncology, Milan, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Colombo
authors.forename: M
authors.initials: M
authors.lastname: Peiretti
authors.forename: G
authors.initials: G
authors.lastname: Parma
authors.forename: M
authors.initials: M
authors.lastname: Lapresa
authors.forename: R
authors.initials: R
authors.lastname: Mancari
authors.forename: S
authors.initials: S
authors.lastname: Carinelli
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: M
authors.initials: M
authors.lastname: Castiglione
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D002277:Carcinoma / Q000145:classification / Q000175:diagnosis* / Q000473:pathology; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008565:Membrane Proteins / Q000097:blood; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins